Literature DB >> 9311880

Mutations in the 5' end of the herpes simplex virus type 2 latency-associated transcript (LAT) promoter affect LAT expression in vivo but not the rate of spontaneous reactivation of genital herpes.

K Wang1, L Pesnicak, S E Straus.   

Abstract

The primary herpes simplex virus type 2 (HSV-2) latency-associated transcript (LAT) promoter influences LAT expression and rates of virus reactivation. We explored the biological importance of particular neuronally responsive regions within the promoter by creating new recombinant viruses bearing a targeted deletion (246 bp [strain 524]) or a point mutation (2 bp [strain 167]) in this region. These recombinant viruses grew efficiently in vitro and in vivo, caused acute genital disease in guinea pigs, and, as measured by quantitative-competitive (QC) DNA PCR, established latency, all as well as did the wild-type parental HSV-2 strain 333, the rescuant strain 524R, and the previously described 624-bp LAT- promoter deletion mutant. By QC-reverse transcriptase PCR of RNA from latently infected ganglia, mutant 167 expressed wild-type levels of LAT and the deletion mutant 524 expressed 9- to 15-fold less LAT than normal, while the LAT expression of the LAT- mutant was undetectable or at least 5 log units less than that of the wild type. The rates of recurrence of genital lesions were normal for recombinant viruses 524 and 167 but reduced (as expected) for the LAT- mutant. Alteration of a subset of LAT promoter elements reduced LAT expression by 1 log unit but did not influence the rate of spontaneous disease reactivation in vivo. Far greater reductions in LAT expression are necessary before reactivation rates are noticeably changed.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9311880      PMCID: PMC192147          DOI: 10.1128/JVI.71.10.7903-7910.1997

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  29 in total

1.  The promoter of the latency-associated transcripts of herpes simplex virus type 1 contains a functional cAMP-response element: role of the latency-associated transcripts and cAMP in reactivation of viral latency.

Authors:  D A Leib; K C Nadeau; S A Rundle; P A Schaffer
Journal:  Proc Natl Acad Sci U S A       Date:  1991-01-01       Impact factor: 11.205

2.  Identification of the latency-associated transcript promoter by expression of rabbit beta-globin mRNA in mouse sensory nerve ganglia latently infected with a recombinant herpes simplex virus.

Authors:  A T Dobson; F Sederati; G Devi-Rao; W M Flanagan; M J Farrell; J G Stevens; E K Wagner; L T Feldman
Journal:  J Virol       Date:  1989-09       Impact factor: 5.103

3.  An HSV-1 mutant lacking the LAT TATA element reactivates normally in explant cocultivation.

Authors:  S L Deshmane; M Nicosia; T Valyi-Nagy; L T Feldman; A Dillner; N W Fraser
Journal:  Virology       Date:  1993-10       Impact factor: 3.616

4.  Herpes simplex virus type 1 latency-associated transcription plays no role in establishment or maintenance of a latent infection in murine sensory neurons.

Authors:  F Sedarati; K M Izumi; E K Wagner; J G Stevens
Journal:  J Virol       Date:  1989-10       Impact factor: 5.103

5.  Two open reading frames (ORF1 and ORF2) within the 2.0-kilobase latency-associated transcript of herpes simplex virus type 1 are not essential for reactivation from latency.

Authors:  M U Fareed; J G Spivack
Journal:  J Virol       Date:  1994-12       Impact factor: 5.103

6.  The latency-associated transcript gene of herpes simplex virus type 1 (HSV-1) is required for efficient in vivo spontaneous reactivation of HSV-1 from latency.

Authors:  G C Perng; E C Dunkel; P A Geary; S M Slanina; H Ghiasi; R Kaiwar; A B Nesburn; S L Wechsler
Journal:  J Virol       Date:  1994-12       Impact factor: 5.103

7.  Quantity of latency-associated transcript produced by herpes simplex virus is not predictive of the frequency of experimental recurrent genital herpes.

Authors:  N Bourne; L R Stanberry; B L Connelly; J Kurawadwala; S E Straus; P R Krause
Journal:  J Infect Dis       Date:  1994-05       Impact factor: 5.226

8.  The nucleotide sequence, 5' end, promoter domain, and kinetics of expression of the gene encoding the herpes simplex virus type 2 latency-associated transcript.

Authors:  P R Krause; J M Ostrove; S E Straus
Journal:  J Virol       Date:  1991-10       Impact factor: 5.103

9.  Herpes simplex virus type 1 latency-associated transcription unit promotes anatomical site-dependent establishment and reactivation from latency.

Authors:  N M Sawtell; R L Thompson
Journal:  J Virol       Date:  1992-04       Impact factor: 5.103

10.  A novel latency-active promoter is contained within the herpes simplex virus type 1 UL flanking repeats.

Authors:  W F Goins; L R Sternberg; K D Croen; P R Krause; R L Hendricks; D J Fink; S E Straus; M Levine; J C Glorioso
Journal:  J Virol       Date:  1994-04       Impact factor: 5.103

View more
  15 in total

Review 1.  Quantitative molecular analysis of virus expression and replication.

Authors:  M Clementi
Journal:  J Clin Microbiol       Date:  2000-06       Impact factor: 5.948

2.  The probability of in vivo reactivation of herpes simplex virus type 1 increases with the number of latently infected neurons in the ganglia.

Authors:  N M Sawtell
Journal:  J Virol       Date:  1998-08       Impact factor: 5.103

3.  Comparative efficacy and immunogenicity of replication-defective, recombinant glycoprotein, and DNA vaccines for herpes simplex virus 2 infections in mice and guinea pigs.

Authors:  Yo Hoshino; Sarat K Dalai; Kening Wang; Lesley Pesnicak; Tsz Y Lau; David M Knipe; Jeffrey I Cohen; Stephen E Straus
Journal:  J Virol       Date:  2005-01       Impact factor: 5.103

4.  Laser-capture microdissection: refining estimates of the quantity and distribution of latent herpes simplex virus 1 and varicella-zoster virus DNA in human trigeminal Ganglia at the single-cell level.

Authors:  Kening Wang; Tsz Y Lau; Melissa Morales; Erik K Mont; Stephen E Straus
Journal:  J Virol       Date:  2005-11       Impact factor: 5.103

5.  A herpes simplex virus 2 glycoprotein D mutant generated by bacterial artificial chromosome mutagenesis is severely impaired for infecting neuronal cells and infects only Vero cells expressing exogenous HVEM.

Authors:  Kening Wang; Justin D Kappel; Caleb Canders; Wilmer F Davila; Dean Sayre; Mayra Chavez; Lesley Pesnicak; Jeffrey I Cohen
Journal:  J Virol       Date:  2012-09-19       Impact factor: 5.103

6.  The 2.2-kilobase latency-associated transcript of herpes simplex virus type 2 does not modulate viral replication, reactivation, or establishment of latency in transgenic mice.

Authors:  K Wang; L Pesnicak; E Guancial; P R Krause; S E Straus
Journal:  J Virol       Date:  2001-09       Impact factor: 5.103

7.  Herpes simplex virus type 2 UL24 gene is a virulence determinant in murine and guinea pig disease models.

Authors:  Susan Blakeney; Jacek Kowalski; Donna Tummolo; Joanne DeStefano; David Cooper; Min Guo; Seema Gangolli; Deborah Long; Timothy Zamb; Robert J Natuk; Robert J Visalli
Journal:  J Virol       Date:  2005-08       Impact factor: 5.103

8.  Comparison of immunogenicity and protective efficacy of genital herpes vaccine candidates herpes simplex virus 2 dl5-29 and dl5-29-41L in mice and guinea pigs.

Authors:  Yo Hoshino; Lesley Pesnicak; Kennichi C Dowdell; Juan Lacayo; Timothy Dudek; David M Knipe; Stephen E Straus; Jeffrey I Cohen
Journal:  Vaccine       Date:  2008-06-02       Impact factor: 3.641

9.  Impairment in reactivation of a latency associated transcript (LAT)-deficient HSV-2 is not solely dependent on the latent viral load or the number of CD8(+) T cells infiltrating the ganglia.

Authors:  Yo Hoshino; Lesley Pesnicak; Stephen E Straus; Jeffrey I Cohen
Journal:  Virology       Date:  2009-03-09       Impact factor: 3.616

10.  Cell type specific accumulation of the major latency-associated transcript (LAT) of herpes simplex virus type 2 in LAT transgenic mice.

Authors:  Kening Wang; Gowtham Mahalingam; Yumi Imai; Lesley Pesnicak; Todd P Margolis; Todd T Margolis; Stephen E Straus; Jeffrey I Cohen
Journal:  Virology       Date:  2009-02-06       Impact factor: 3.616

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.